Apichope Pharmaceutical announcement: The drug clinical trial application for the four-valent influenza recombinant protein vaccine independently developed by its holding subsidiary, Guangdong South China Vaccine Co., Ltd., has been approved by the National Medical Products Administration, and has received the 'Drug Clinical Trial Approval Notice'. This vaccine is used to prevent the epidemic influenza caused by infection of four types of influenza viruses, type A and type B, in people aged 18 and above. The company stated that the approval of the clinical trial will not have a significant impact on the company's short-term financial conditions and operational performance.